IGF-I replacement therapy in children with congenital IGF-I deficiency (Laron syndrome) maintains heart dimension and function

Growth Hormone and IGF Research

Volumn 19, Issue 3, 2009, Pages 280-282

  Scheinowitz, Mickey ^a,b   Feinberg, Micha S ^a   Laron, Zvi ^a  

^a TEL AVIV UNIVERSITY   (Israel)

^b WASHINGTON HOSPITAL CENTER   (United States)

Author keywords

Congenital IGF I deficiency; Echocardiography; Insulin like growth factor I; Laron syndrome

Indexed keywords

FK 780; RECOMBINANT SOMATOMEDIN C; UNCLASSIFIED DRUG;

ARTICLE; BODY HEIGHT; BODY SURFACE; BODY WEIGHT; CHILD; CLINICAL ARTICLE; CONTINUOUS INFUSION; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; ECHOCARDIOGRAPHY; FEMALE; GROUPS BY AGE; HEART FUNCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE MASS; HEART LEFT VENTRICLE WALL; HEART SIZE; HORMONE SUBSTITUTION; HUMAN; LARON SYNDROME; MALE; NOMOGRAM; PRIORITY JOURNAL; SEX DIFFERENCE; SYSTOLIC BLOOD PRESSURE;

CARDIAC VOLUME; CHILD; CHILD, PRESCHOOL; ECHOCARDIOGRAPHY; FEMALE; HEART; HEART DEFECTS, CONGENITAL; HEART VENTRICLES; HUMAN GROWTH HORMONE; HUMANS; INFANT; INSULIN-LIKE GROWTH FACTOR I; LARON SYNDROME; MALE; VENTRICULAR FUNCTION, LEFT;

EID: 67349260154     PISSN: 10966374     EISSN: 15322238     Source Type: Journal    
DOI: 10.1016/j.ghir.2008.11.004     Document Type: Article

References (11)

1. Laron Z. Laron syndrome (primary growth hormone resistance or insensitivity). The personal experience 1958-2003. J. Clin. Endocrinol. Metab. 89 (2004) 1031-1044
2. Laron Z. Consequences of not treating children with Laron syndrome (primary growth hormone insensitivity). J. Pediatr. Endocrinol. Metab. 14 (2001) 1243-1248
3. Besson A., Salemi S., Eblé A., Joncourt F., Gallati S., Jorge AA., and Mullis PE. Primary GH insensitivity (Laron syndrome) caused by a novel 4 kb deletion encompassing exon five of the GH receptor gene: effect of intermittent long-term treatment with recombinant human IGF-I. Eur. J. Endocrinol. 150 (2004) 635-642
4. Klinger B., and Laron Z. Three year IGF-I treatment of children with Laron syndrome. J. Pediatr. Endocrinol. Metab. 8 (1995) 149-158
5. Sivan B., Lilos P., and Laron Z. Effects of insulin-like growth factor-I deficiency and replacement therapy on the hematopoietic system in patients with Laron syndrome (primary growth hormone insensitivity). J. Pediatr. Endocrinol. Metab. 16 (2003) 509-520
6. Feinberg M.S., Scheinowitz M., and Laron Z. Echocardiographic dimensions and function in adults with primary growth hormone resistance (Laron syndrome). Am. J. Cardiol. 85 (2000) 209-213
7. Salerno M., Esposito V., Farina V., et al. Improvement of cardiac performance and cardiovascular risk factors in children with GH deficiency after two years of GH replacement therapy: an observational, open, prospective, case-control study. J. Clin. Endocrinol. Metab. 91 (2006) 1288-1295
8. Jallad R.S., Liberman B., Vianna C.B., Vieira M.L., Ramires J.A., and Knoepfelmacher M. Effects of growth hormone replacement therapy on metabolic and cardiac parameters, in adult patients with childhood onset growth hormone deficiency. Growth Horm. IGF Res. 13 (2003) 81-88
9. Colao A., di Somma C., Cuocolo A., et al. Improved cardiovascular risk factors and cardiac performance after 12 months of growth hormone (GH) replacement in young adult patients with GH deficiency. J. Clin. Endocrinol. Metab. 86 (2001) 1874-1881
10. McCallum R.W., Petrie J.R., Dominiczak A.F., and Connell J.M. Growth hormone deficiency and vascular risk. Clin. Endocrinol. (Oxf). 54 (2002) 11-24
11. Vasconez O., Martinez V., Martinez A.L., et al. Heart rate increases in patients with growth hormone receptor deficiency treated with insulin-like growth factor-I. Acta Paediatr. 399 Suppl. (1994) 137-139